Lerociclib

来罗西利

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameLerociclib
Drug Alias Name盐酸来罗西利Lerociclib Hydrochloride汝佳宁G1T38-1G1T-38 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsMetastatic breast cancer
Approved Indications in ChinaMetastatic breast cancer
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryBelgiumBulgariaUnited States +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesG1 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEdding Genor Group Holdings LtdGenor Biopharma(USA) IncPepper Bio Inc +[6] 
Inactive CompaniesEqrx Inc
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Inactive IndicationsEndometrial Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A